William P Forbes
CIK 1314760 · EVP, Chief Development Officer · last filed 2026-08-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$76.9K
Companies
4
Total Filings
74
Lifetime Open-Market Net
-$16.39M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HRTX | EVP, Chief Development Officer | 241,173 | $0.32 | $76.7K | $74.2K | 24 | 2026-08-03 |
| XAIR | Director | 37 | $5.30 | $196 | $90.7K | 10 | 2025-11-06 |
| TRVI | Chief Development Officer | — | $17.59 | — | $0 | 4 | 2022-07-01 |
| SALIX PHARMACEUTICALS LTD (SLXP) Delisted | President, Medical R&D and CDO | 51,714 | — | — | -$16.55M | 35 | 2015-03-11 |
Recent Filings · Page 7 of 8
74 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-07-06 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Tax (F) | −9,212 | -$366.9K | EDGAR |
| 2011-05-18 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Mixed | — | -$456.4K | EDGAR |
| 2011-05-04 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Grant (A) | +22,698 | $0 | EDGAR |
| 2010-11-12 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Mixed | — | -$224.8K | EDGAR |
| 2010-09-16 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Sell (S) | −10,695 | -$433.1K | EDGAR |
| 2010-07-21 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Grant (A) | +15,055 | $0 | EDGAR |
| 2010-07-06 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Tax (F) | −7,586 | -$296.1K | EDGAR |
| 2010-04-16 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Mixed | — | -$225.0K | EDGAR |
| 2010-04-05 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Sell (S) | −1,879 | -$71.4K | EDGAR |
| 2009-12-28 | SALIX PHARMACEUTICALS LTD (SLXP) Delisted | Sell (S) | −5,000 | -$125.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.